1116.4000 5.50 (0.50%)
NSE Jun 22, 2026 12:23 PM
Volume: 50,584
 

1116.40
0.50%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma has gained 35.03% in the last 1 Year
More from Strides Pharma Science Ltd.
Recommended